Latest Administration News

Equity Story Group Ltd (ASX – EQS) has announced a fully underwritten renounceable entitlement offer to raise approximately $3.54 million, aiming to accelerate its entry into the property sector and strengthen working capital.

Tivan Limited has formalized a three-year strategic partnership with New York-based Exante Data to deepen analytics and policy advisory in the rapidly evolving critical minerals sector.

Moho Resources has reported new high-grade gold assays up to 6.98g/t at its Bush Chook Project in Western Australia, extending a mineralised trend to 300 metres and setting the stage for a maiden drill program later this year or early next.

EVE Health Group Limited has launched a $1.1 million capital raising via a placement to fund the commercial rollout of its two pharmaceutical products, Dyspro and Libbo. The offer includes shares and options, with some subject to shareholder approval.

Triton Minerals advances its graphite sale resolution with NQM while initiating key field activities at the Aucu Gold-Copper Project in Mozambique, alongside launching a shareholder consolidation scheme.

Netlinkz Limited has attributed the late filing of a key director disclosure to an administrative error, while affirming its existing compliance frameworks remain robust.

Bod Science reports a $576k cash outflow in Q1 FY2026 amid ongoing administration and delays in Biortica audit completion. The company plans a shareholder vote in November to approve its acquisition of Biortica and exit from administration.

Bod Science Limited reported a $576,000 net operating cash outflow for the September quarter, sustained by funding from Biortica Agrimed Limited under a Deed of Company Arrangement as it pursues a backdoor listing.

Highfield Resources has locked in A$10 million through convertible notes from existing investors to tackle a key permit issue and push forward its flagship Muga Potash Project in Spain.

Clarity Pharmaceuticals’ Co-PSMA Phase II trial shows its Cu-SAR-bisPSMA diagnostic agent detects more prostate cancer lesions than current standard imaging, promising earlier and more accurate recurrence detection.

Pacific Edge reports a 9% decline in Cxbladder test volumes amid Medicare coverage loss but gains momentum with new clinical validation and a CMS pricing boost.

Clime Investment Management has completed a $2.3 million placement and announced a bonus option issue, positioning itself for growth as the Australian wealth management sector consolidates.